RT Journal Article
T1 Transforming Growth Factor-β3 Regulates Adipocyte Number in Subcutaneous White Adipose Tissue
A1 Petrus, Paul et al.
A1 Rydén M., 
A1 Maldonado Bautista, Estela
A1 Martínez Álvarez, María Concepción
AB White adipose tissue (WAT) mass is determined by adipocyte size and number. While adipocytes are continuously turned over, the mechanisms controlling fat cell number in WAT upon weight changes are unclear. Herein, prospective studies of human subcutaneous WAT demonstrate that weight gain increases both adipocyte size and number, but the latter remains unaltered after weight loss. Transcriptome analyses associate changes in adipocyte number with the expression of 79 genes. This gene set is enriched for growth factors, out of which one, transforming growth factor-b3 (TGFb3), stimulates adipocyte progenitor proliferation, resulting in a higher number of cells undergoing differentiation in vitro. The relevance of these observations was corroborated in vivo where Tgfb3+/  mice, in comparison with wild-type littermates, display lower subcutaneous adipocyte progenitor proliferation, WAT hypertrophy, and glucose intolerance. TGFb3 is therefore a regulator of subcutaneous adipocyte number and may link WAT morphology to glucose metabolism.
PB Cell Press
SN 2211-1247
YR 2017
FD 2017
LK https://hdl.handle.net/20.500.14352/101438
UL https://hdl.handle.net/20.500.14352/101438
LA eng
NO cite Petrus P, Mejhert N, Corrales P, Lecoutre S, Li Q, Maldonado E, Kulyté A, Lopez Y, Campbell M, Acosta JR, Laurencikiene J, Douagi I, Gao H, Martínez-Álvarez C, Hedén P, Spalding KL, Vidal-Puig A, Medina-Gomez G, Arner P, Rydén M. Transforming Growth Factor-β3 Regulates Adipocyte Number in Subcutaneous White Adipose Tissue. Cell Rep. 2018 Oct 16;25(3):551-560.e5.
NO Strategic Research Program in Diabetes at Karolinska Institutet
NO Diabetes Wellness Fund
NO Stockholm County Council
NO Swedish Diabetes Foundation
NO European Association on the Study of Diabetes
NO Novo Nordisk Foundation
NO Swedish Research Council
DS Docta Complutense
RD 27 abr 2025